Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 2,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Neoadjuvant therapy Clear all

Conditions: Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
Interventions: Enfortumab vedotin, Pembrolizumab, Cisplatin, Gemcitabine, Fluorouracil, Mitomycin c, Radical cystectomy, Radiation therapy; Drug · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Motolimod, Cetuximab, Nivolumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Kansas City, Missouri • New York, New York • Nashville, Tennessee

Conditions: Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer, Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
Interventions: Cisplatin, Pemetrexed, Gemcitabine; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Goodyear, Arizona

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim, busulfan, cyclosporine, melphalan, methylprednisolone, flow cytometry, immunologic technique, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation; Biological · Drug · Other + 1 more
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Breast Cancer
Interventions: Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 45
States / cities: Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more

Conditions: Prostate Cancer
Interventions: bicalutamide, leuprolide acetate, adjuvant therapy, neoadjuvant therapy, quality-of-life assessment, brachytherapy; Drug · Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Uveal Melanoma
Interventions: Darovasertib; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 10
States / cities: Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 7 more

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy; Procedure · Other · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 75 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2075
U.S. locations: 164
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more

Conditions: Breast Cancer
Interventions: Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 4
States / cities: Iowa City, Iowa • Royal Oak, Michigan • Portland, Oregon + 1 more

Conditions: Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions: Posaconazole, ABT-199, Decitabine, Azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 60 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 13
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Leukemia, Lymphoma
Interventions: dactinomycin, sargramostim, carmustine, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, mercaptopurine, methotrexate, mitoxantrone hydrochloride, pegaspargase, prednisone, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Stanford, California • Atlanta, Georgia + 4 more

Conditions: Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Interventions: Durvalumab, Paclitaxel, Carboplatin, Radiation, Surgical Resection; Device · Drug · Radiation + 1 more
Lead sponsor: Greg Durm, MD; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • New York, New York + 1 more

Conditions: Venous Thromboembolism, Ovarian Cancer
Interventions: Aspirin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Sarasota, Florida • Durham, North Carolina

Conditions: High-risk Prostate Cancer
Interventions: Neoadjuvant Epigenetic Therapy; Drug
Lead sponsor: Edwin Posadas, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Breast Carcinoma, Breast Tumors
Interventions: Letrozole, palbociclib; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Long Beach, California • Miami, Florida • Decatur, Illinois + 13 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions: Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure; Drug · Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 97
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more

Conditions: Basal Cell Carcinoma of the Head and Neck
Interventions: Pembrolizumab, Tissue collection; Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Esophageal Cancer
Interventions: PPX with cisplatin and radiation; Drug
Lead sponsor: Brown University; Other
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Breast Neoplasm
Interventions: RAD001, Letrozole 2.5mg, Letrozole 2.5mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 10
States / cities: Springdale, Arkansas • Long Beach, California • San Francisco, California + 7 more

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Carboplatin, Nab-paclitaxel, GM-CSF, Trastuzumab, Bevacizumab; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Orange, California

Conditions: Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
Interventions: Cemiplimab, Computed Tomography, Biospecimen Collection, Quality-of-Life Assessment, Magnetic Resonance Imaging, Biopsy, Fianlimab; Biological · Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 3
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: Rectal Cancer
Interventions: Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin, Capecitabine (Xeloda®), intensity modulated radiotherapy (IMRT), Quality of Life Questionnaires, DRE-Endoscopy; Drug · Radiation · Behavioral + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 26
States / cities: Irvine, California • Orange, California • San Francisco, California + 22 more

Conditions: Prostate Cancer
Interventions: Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation; Biological · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Quantitative MRI Assessment of Breast Cancer Therapy Response

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

Neoadjuvant Treatment of Breast Cancer

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer